Insider Selling: Kane Biotech Inc. (CVE:KNE) Director Sells C$260,000.00 in Stock

Kane Biotech Inc. (CVE:KNE) Director Philip Renaud sold 2,000,000 shares of the company’s stock in a transaction that occurred on Wednesday, April 17th. The stock was sold at an average price of C$0.13, for a total value of C$260,000.00.

Kane Biotech Price Performance

Shares of CVE:KNE opened at C$0.13 on Thursday. Kane Biotech Inc. has a twelve month low of C$0.05 and a twelve month high of C$0.17. The stock’s 50 day moving average is C$0.11 and its 200-day moving average is C$0.09. The company has a quick ratio of 0.39, a current ratio of 0.37 and a debt-to-equity ratio of 1,164.24. The firm has a market capitalization of C$16.48 million, a price-to-earnings ratio of -4.17 and a beta of 0.56.

Kane Biotech (CVE:KNE) last released its quarterly earnings data on Tuesday, March 26th. The company reported C($0.01) earnings per share for the quarter. The business had revenue of C$0.04 million for the quarter.

Kane Biotech Company Profile

Kane Biotech Inc, a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops pet oral care products under the StrixNB and bluestem brands; and animal and human wound care solutions under the DispersinB name.